Marshall Wace, LLP I Mab Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in I Mab stock. As of the latest transaction made, Marshall Wace, LLP holds 14,064 shares of IMAB stock, worth $17,439. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,064
Previous 71,088
80.22%
Holding current value
$17,439
Previous $132,000
82.58%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding IMAB
# of Institutions
44Shares Held
16.4MCall Options Held
3KPut Options Held
1.9K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$8.57 Million0.3% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$5.17 Million3.04% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.38MShares$1.71 Million0.07% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny577KShares$714,9840.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0567KShares$702,6460.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $103M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...